We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Following last week's dramatic decision to reverse a reported agreement between Brazil's government and US firm Abbott Laboratories, the stand-off appears to be spreading to bilateral trade talks at the World Trade Organisation (WTO).
The Ukraine's US$1.1bn pharmaceutical market is likely to see solid growth in the next few years, with imports accounting for nearly 77% of sales in 2004.
Crucell NV and its manufacturing partner DSM NV said they signed a deal to license
Crucell's PER.C6 cell line technology to Danish biotechnology company Symphogen
AS.
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced
on July 8, 2005, the establishment of a pharmaceuticals marketing subsidiary,
Eisai AB, in Sweden to expand business in the four Nordic countries (Sweden,
Denmark, Finland and Norway).
Swiss drugmaker Novartis (NOVN.VX: Quote, Profile, Research) said on Thursday
it will pay $660 million for the rights to produce and market Bristol-Myers
Squibb Co.'s (BMY.N: Quote, Profile, Research) North American over-the-counter
products, including the painkiller Excedrin. Other brands included in the deal
are Keri, No-Doz, and Comtrex, Novartis said in a statement.